{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T09:58:41Z","timestamp":1792403921229,"version":"4.4.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T00:00:00Z","timestamp":1595980800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T00:00:00Z","timestamp":1595980800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      To evaluate\n                      <jats:sup>106<\/jats:sup>\n                      Ruthenium Brachytherapy in management of medium sized uveal melanoma, with emphasis on 5-year outcome and toxicity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>From April 2007 to October 2015, 39 patients with medium sized uveal melanoma were treated with 106 Ru eye plaques brachytherapy. At the time of diagnosis, the mean tumor depth was 3.7\u2009mm (\u00b1SD:1.6\u2009mm). The mean dose at the tumor apex was 141.4\u2009Gy (\u00b1 SD: 12.1\u2009Gy) and 557.7\u2009Gy (\u00b1 SD: 257.3\u2009Gy) to the sclera.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Mean follow-up was 69.5\u2009months (\u00b1 SD: 53.8\u2009months). Thirty-four patients (87.1%) remained free of recurrence. Twenty-six patients (66.7%) demonstrated a complete tumor regression after a median period of 12\u2009months (3\u201360 mon.). By the final examination, the visual acuity of 26 patients (66.7%) was better than 20\/200, and 12 patients (30.7%) had a visual acuity better than 20\/40.<\/jats:p>\n                    <jats:p>Retinopathy was detected in 11 patients (28.2%). After treatments only one patient (5.1%) had active vascular changes by the last examination. Moderate optic neuropathy was observed in 4 patients (10.3%). Cataract development was diagnosed in 21 patients (53.8%), and 16 patients (41%) had bilateral cataract development.<\/jats:p>\n                    <jats:p>Special emphasis was made on patients with larger tumors. Twelve out of the 39 patients had a tumor with a depth of 5\u2009mm or more. There was no significant difference in local control or in side effects between both groups observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Our study proved\n                      <jats:sup>106<\/jats:sup>\n                      Ru -brachytherapy to be an excellent treatment option with regard to tumor control and preservation of the visual acuity in well-selected patients. Our data suggested that this treatment is also suitable for tumors with a depth of more than 5\u2009mm.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13014-020-01621-4","type":"journal-article","created":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T08:02:39Z","timestamp":1596009759000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["106Ruthenium eye plaque brachytherapy in the management of medium sized uveal melanoma"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7890-6713","authenticated-orcid":false,"given":"Ping","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantine","family":"Purtskhvanidze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerit","family":"Kandzia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Luetzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank-Andr\u00e9","family":"Siebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"Roider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juergen","family":"Dunst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,29]]},"reference":[{"key":"1621_CR1","doi-asserted-by":"crossref","unstructured":"Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. twelve-year mortality rates and prognostic factors: COMS report no. 28. Arch Ophthalmol. 2006;124(12):1684\u201393.","DOI":"10.1001\/archopht.124.12.1684"},{"issue":"3","key":"1621_CR2","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.prro.2014.09.005","volume":"5","author":"V Takiar","year":"2015","unstructured":"Takiar V, Voong KR, Gombos DS, Mourtada F, Rechner LA, Lawyer AA, et al. A choice of radionuclide: comparative outcomes and toxicity of ruthenium-106 and iodine-125 in the definitive treatment of uveal melanoma. Pract Radiat Oncol. 2015;5(3):169\u201376.","journal-title":"Pract Radiat Oncol"},{"key":"1621_CR3","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1259\/bjr\/76813976","volume":"81","author":"DA Wilkinson","year":"2008","unstructured":"Wilkinson DA, Kolar M, Fleming PA, Singh AD. Dosimetric comparison of 106Ru and 125I plaques for treatment of shallow (<or=5 mm) choroidal melanoma lesions. Br J Radiol. 2008;81:784\u20139.","journal-title":"Br J Radiol"},{"key":"1621_CR4","doi-asserted-by":"publisher","unstructured":"Thomson RM, Furutani KM, Kaulich TW, Mourtada F, Rivard MJ, Soares CG, et al. AAPM recommendations on medical physics practices for ocular plaque brachytherapy: report of task group 221. Med Phys. 2019. https:\/\/doi.org\/10.1002\/mp.13996.","DOI":"10.1002\/mp.13996"},{"key":"1621_CR5","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0161-6420(02)01277-0","volume":"109","author":"LM Jampol","year":"2002","unstructured":"Jampol LM, Moy CS, Murray TG, et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: IV. Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS report no. 19. Ophthalmology. 2002;109:2197\u2013206.","journal-title":"Ophthalmology"},{"key":"1621_CR6","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ijrobp.2014.01.026","volume":"89","author":"BA Perez","year":"2014","unstructured":"Perez BA, Mettu P, Vajzovic L, et al. Uveal melanoma treated with iodine-125 episcleral plaque: an analysis of dose on disease control and visual outcomes. Int J Radiat Oncol Biol Phys. 2014;89:127\u201336.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1621_CR7","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.brachy.2009.03.189","volume":"8","author":"R Correa","year":"2009","unstructured":"Correa R, Pera J, G\u00f3mez J, et al. (125) I episcleral plaque brachytherapy in the treatment of choroidal melanoma: a single-institution experience in Spain. Brachytherapy. 2009;8:290\u20136.","journal-title":"Brachytherapy"},{"issue":"4","key":"1621_CR8","doi-asserted-by":"publisher","first-page":"337","DOI":"10.5114\/jcb.2018.77849","volume":"10","author":"D Miguel","year":"2018","unstructured":"Miguel D, de Frutos-Baraja JM, L\u00f3pez-Lara F, et al. Radiobiological doses, tumor, and treatment features influence on local control, enucleation rates, and survival after epiescleral brachytherapy. A 20-year retrospective analysis from a single-institution: part I. J Contemp Brachytherapy. 2018;10(4):337\u201346.","journal-title":"J Contemp Brachytherapy"},{"key":"1621_CR9","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.ijrobp.2006.01.020","volume":"65","author":"R Dendale","year":"2006","unstructured":"Dendale R. Lumbroso- Le Rouic L, noel G, et al: proton beam radiotherapy for uveal melanoma: results of curie Institut- Orsay proton therapy center (ICPO). Int J Radiat Oncol Biol Phys. 2006;65:780\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1621_CR10","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ijrobp.2009.07.1688","volume":"78","author":"JP Caujolle","year":"2010","unstructured":"Caujolle JP, Mammar H, Chamorey E, Pinon F, Herault J, Gastaud P. Proton beam radiotherapy for uveal melanomas at nice teaching hospital: 16 years\u2019 experience. Int J Radiat Oncol Biol Phys. 2010;78:98\u2013103.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1621_CR11","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1001\/archopht.120.12.1665","volume":"120","author":"E Gragoudas","year":"2002","unstructured":"Gragoudas E, Li W, Goitein M, Lane AM, Munzenrider JE, Egan KM. Evidence- based estimates of outcome in patients irradiated for intraocular melanoma. Arch Ophthalmol. 2002;120:1665\u201371.","journal-title":"Arch Ophthalmol"},{"key":"1621_CR12","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.brachy.2015.04.010","volume":"14","author":"AW Browne","year":"2015","unstructured":"Browne AW, Dandapani SV, Jennelle R, et al. Outcomes of medium choroidal melanomas treated with ruthenium brachytherapy guided by three-dimensional pretreatment modeling. Brachytherapy. 2015;14:718\u201325.","journal-title":"Brachytherapy"},{"issue":"1","key":"1621_CR13","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ijrobp.2012.08.026","volume":"86","author":"Z Wang","year":"2013","unstructured":"Wang Z, Nabhan M, Schild SE, Stafford SL, Petersen IA, Foote RL, et al. Charged particle radiation therapy for uveal melanoma: a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys. 2013;86(1):18\u201326.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1621_CR14","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1159\/000328257","volume":"49","author":"L Desjardins","year":"2012","unstructured":"Desjardins L, Lumbroso-Le Rouic L, Levy-Gabriel C, Cassoux N, Dendale R, Mazal A, et al. Treatment of uveal melanoma by accelerated proton beam. Dev Ophthalmol. 2012;49:41\u201357.","journal-title":"Dev Ophthalmol"},{"issue":"2","key":"1621_CR15","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/S0161-6420(00)00526-1","volume":"108","author":"BM Melia","year":"2001","unstructured":"Melia BM, Abramson DH, Albert DM, et al. Collaborative ocular melanoma study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma. I. Visual acuity after 3 years COMS report no. 16. Ophthalmology. 2001;108(2):348\u201366.","journal-title":"Ophthalmology"},{"issue":"6","key":"1621_CR16","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1001\/jamaophthalmol.2016.0104","volume":"134","author":"HA Aziz","year":"2016","unstructured":"Aziz HA, Singh N, Bena J, et al. Vision loss following Episcleral brachytherapy for uveal melanoma: development of a vision prognostication tool. JAMA Ophthalmol. 2016;134(6):615\u201320.","journal-title":"JAMA Ophthalmol"},{"issue":"6","key":"1621_CR17","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.brachy.2018.07.002","volume":"17","author":"BHA Le","year":"2018","unstructured":"Le BHA, Kim JW, Deng H, et al. Outcomes of choroidal melanomas treated with eye physics plaques: a 25-year review. Brachytherapy. 2018;17(6):981\u20139.","journal-title":"Brachytherapy"},{"issue":"6","key":"1621_CR18","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.brachy.2014.04.002","volume":"13","author":"JH Francis","year":"2014","unstructured":"Francis JH, Cohen GN, Marr BP, Wolden SL, McCormick B, et al. (106) Ru plaque brachytherapy for uveal melanoma: factors associated with local tumor recurrence. Brachytherapy. 2014;13(6):584\u201390.","journal-title":"Brachytherapy."},{"key":"1621_CR19","doi-asserted-by":"crossref","unstructured":"Espensen CA, Appelt AL, Fog LS, Gothelf AB, Thariat J, Kiilgaard JF. Predicting visual acuity deterioration and radiation-induced toxicities after brachytherapy for choroidal melanomas. Cancers (Basel). 2019;11(8):1124.","DOI":"10.3390\/cancers11081124"},{"key":"1621_CR20","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1097\/00000421-198704000-00050","volume":"10","author":"PK Lommatzsch","year":"1987","unstructured":"Lommatzsch PK. Results after beta-irradiation (106Ru\/106Rh) of choroidal melanomas. Twenty years\u2019 experience. Am J Clin Oncol. 1987;10:146\u201351.","journal-title":"Am J Clin Oncol"},{"key":"1621_CR21","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1600-0420.1997.tb00241.x","volume":"75","author":"S Seregard","year":"1997","unstructured":"Seregard S, Aft Trampe E, Lax I, Kock E, Lundell G. Results following episcleral ruthenium plaque radiotherapy for posterior uveal melanoma. The Swedish experience. Acta Ophthalmol Scand. 1997;75:11\u20136.","journal-title":"Acta Ophthalmol Scand"},{"key":"1621_CR22","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.ijrobp.2005.02.017","volume":"63","author":"B Damato","year":"2005","unstructured":"Damato B, Patel I, Campbell IR, Mayles HM, Errington RD. Local tumor control after 106Ru brachytherapy of choroidal melanoma. Int J Radiat Oncol Biol Phys. 2005;63:385\u201391.","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-020-01621-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-020-01621-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-020-01621-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T19:13:33Z","timestamp":1627499613000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-020-01621-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,29]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1621"],"URL":"https:\/\/doi.org\/10.1186\/s13014-020-01621-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-20855\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-20855\/v2","asserted-by":"object"}]},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,29]]},"assertion":[{"value":"1 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"183"}}